Across TCGA pan-cancer cohorts, BRCC3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BRCC3 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BRCC3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BRCC3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where BRCC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	22	view →
PDAC	DFS	Median	II,III,IV	0.902	0.595	.004	17	view →
UCEC	OS	Median	All	0.841	0.962	.017	6	view →
HNSC	DFS	Median	IV	1.000	0.924	.037	3	view →
LUAD	DFS	Median	All	0.750	0.504	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BRCC3 tumor-vs-normal RNA expression · all BRCC3 data types